The volume sheds new light on role of gut dysbiosis in cancer and immunological diseases and their clinical manifestations. Contributions in the volume discuss about the gut microbiota as a therapeutic target and the role of probiotics in its management. The volume explores application of probiotics in the treatment of various cancers viz. colorectal, gastric, lung, and breast cancer and immunological diseases. The volume comprises of chapters from expert contributors organized into various important themes which include, introduction, relationship between gut microbiota and disease condition, mechanisms involved, clinical and in vivo status, conclusion and future directions. This is a highly informative and carefully presented book, providing recent and innovative insight for scholars and researchers with an interest in probiotics and its applications in cancer and immunological diseases.

Dr Indu Pal Kaur is presently the Professor and Chairperson, at the University Institute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh, India. She has more than 25 years of teaching and research experience to her credit. She was Director Sophisticated Analytical Instrumentation Facility, Panjab University, from 2012 to 2015 and Dean - Faculty of Pharmaceutical Sciences, for session 2017-18. Her research forte is enhancing bioperformance of drugs, plant extracts/phytochemicals and small/large biomolecules viz. siRNA and probiotics using active-tailored delivery systems. She has been granted four Indian and one US patents and has filed 22 patents in the past 10 years. She has produced 23 PhDs and 55 postgraduates. She received funding to the tune of 72.3 million INR from Government agencies and has a couple of Industrial consultancies amounting to 15.3 million INR. Her research work was funded twice (2017 and 2020) by DST and Science and Techno^ 130 high impact International publications, and her group has received 31 Best Paper awards at National and International Conferences. She is a US-Fulbright fellow (2017-18) and was awarded Women Scientist Award -2018 by Organisation of Pharmaceutical Producers of India (OPPI). She has also been graced with BRIC Technology Exposition Award, consecutively for 2019 and 2020, Tynor Innovation Award- 2019 and Researcher of the Year award 2019, by Sunpure Research Incubation Center. Emphasis of her work lies on Industrial and clinical translation and is reflected through her three technology transfers to two Indian industries.
Dr Parneet Kaur Deol, is presently working as Assistant Professor at G.H.G. Khalsa College of Pharmacy Gurusar Sadhar Ludhiana, Punjab, India. She has more than 10 years of experience in probiotic research and has published her work in highly reputed peer reviewed international journals. She has 21 international publications to her credit with cumulative impact^50. She has co-edited a special issue for Current Pharmaceutical Design with Prof. Indu Pal Kaur in the year 2019. Dr Deol has presented her work at various national and international platforms. She was awarded with the Dr. Harpal Singh Buttar and Mrs. Harinder Kaur Buttar Award of Excellence in Pharmaceutical Sciences in the year 2016 and Mekaster Young Scientist Award in 2018 for her research work. Recently she fetched two research projects from Department of Science and Technology-Science and Engineering Research Board (DST-SERB), New Delhi worth 65 lakh.

Chapter 1: Gut Microbiota and Cancer Correlates.- Chapter 2: Potential Preventive and Therapeutic Accountability of Probiotics in Cancer: An Insight of Mechanism of Action.- Chapter 3: Probiotics and Cancer: Boosting the Immune System.- Chapter 4: Probiotics as Next Generation Strategy for Cancer Therapy.- Chapter 5: Metabiotics in Colorectal Cancer: Crosstalk between Gut Microbiota and Host Pathology.- Chapter 6: Possibility of Probiotic in Colorectal Cancer: A Specific Countenance to Research.- Chapter 7: Probiotics in Lung Cancer: An Emerging Field of Multifarious Potential and Opportunities.- Chapter 8: Probiotics for Prophylaxis and Management of Breast Cancer: Preclinical and Clinical Evidence.- Chapter 9: Probiotics for Management of Gastrointestinal Cancers.- Chapter 10: Potential of Probiotics in the Management of Lung Cancers.- Chapter 11: Bacteriocins of Probiotics as Potent Anticancer Agents.- Chapter 12: Probiotics in Autoimmune and Inflammatory Diseases.- Chapter 13: Role of Probiotics in Rheumatoid Arthritis.- Chapter 14: Genetically Engineered Probiotics.- Chapter 15: A Glance to the Patent World of Probiotics.